ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,011.12
-0.22%
US Tech 100
16,883.60
-0.31%
Dow Jones
37,775.38
0.00%
Brent Oil
85.955
-0.53%
Bitcoin
65,296.36
2.79%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Gilead Sciences Inc (GILD) Quote

Gilead Sciences Inc

Gilead Sciences Inc (GILD)

DMG Mori AG
DMG Mori AG
DMG Mori AG
DMG Mori AG
Guild Esports Plc
66.16
-0.77
(-1.15%)
Closed April 18 4:00PM
Delayed by 15 minutes
66.36
0.20
( 0.30% )
Pre Market: 8:01AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
66.36
Bid
66.36
Ask
66.51
Volume
876
0.00 Day's Range 0.00
65.90 52 Week Range 87.865
Market Cap
82.42B
Previous Close
66.16
Open
-
Last Trade
1
@
66.16
Last Trade Time
08:01:13
Financial Volume
-
VWAP
-
Average Volume (3m)
7,161,908
Shares Outstanding
1,245,774,616
Dividend Yield
4.55%
PE Ratio
14.55
Earnings Per Share (EPS)
4.55
Revenue
27.12B
Net Profit
5.67B

About Gilead Sciences Inc

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.gilead.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GILD. The last closing price for Gilead Sciences was $66.16. Over the last year, Gilead Sciences shares have traded in a share price range of $ 65.90 to $ 87.865.

Gilead Sciences currently has 1,245,774,616 shares outstanding. The market capitalization of Gilead Sciences is $82.42 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 14.55.

Gilead Sciences (GILD) Options Flow Summary

GILD Options Flow

Overall Flow

Bearish

Net Premium

-17M

Calls / Puts

29.03%

Buys / Sells

280.00%

OTM / ITM

33.33%

Sweeps Ratio

0.00%

GILD Latest News

More News

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m...

April 08 2024
Business Wire

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

– Efficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the...

March 28 2024
Business Wire

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

— Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers — Gilead Sciences...

March 28 2024
Business Wire

Gilead Sciences Announces Completion of Acquisition of CymaBay

Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously...

March 22 2024
Business Wire

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the...

March 18 2024
Business Wire

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

March 11 2024
Edgar (US Regulatory)

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender...

March 11 2024
Business Wire

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

– New Data Evaluating the Efficacy and Safety Profile of Biktarvy for the Treatment of People with HIV and Hepatitis B or Tuberculosis will be Presented – – Retrospective Analysis Evaluating HIV...

March 06 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.16-3.152364273268.5268.6265.9596906467.25316795CS
4-6.75-9.2326631103873.1173.8765.9619982670.10308856CS
12-13.87-17.28779758280.2380.5165.9716190873.16635075CS
26-12.71-16.074364487279.0787.86565.9691628976.56998705CS
52-17.1-20.488856937583.4687.86565.9625354677.17100461CS
156-0.34-0.50974512743666.789.7457.165710824271.6011499CS
2604.266.8599033816462.189.7456.56827513570.33369638CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZCMDZhongchao Inc
$ 3.04
(109.66%)
7.68M
RWODURedwoods Acquisition Corporation
$ 17.50
(65.41%)
2.96k
RWODRedwoods Acquisition Corporation
$ 12.66
(58.32%)
1.27M
EGOXNext e GO NV
$ 0.0482
(33.89%)
17.16M
WLGSWang and Lee Group Inc
$ 0.623
(24.60%)
602.65k
DCFCTritium DCFC Ltd
$ 1.23
(-66.21%)
197.34k
NXLNexalin Technologies Inc
$ 0.98
(-33.33%)
26.33k
BGLCBioNexus Gene Lab Corporation
$ 0.6475
(-23.70%)
49.18k
ISPCiSpecimen Inc
$ 0.344
(-18.29%)
189.53k
TIRXTian Ruixiang Holdings Ltd
$ 0.661
(-17.38%)
267.18k
EGOXNext e GO NV
$ 0.0482
(33.89%)
17.16M
ZCMDZhongchao Inc
$ 3.04
(109.66%)
7.68M
SQQQProShares UltraPro Short QQQ
$ 12.22
(1.24%)
4.06M
SINTSiNtx Technologies Inc
$ 0.0426
(6.50%)
3.57M
HUBCHub Cyber Security Ltd
$ 1.51
(17.05%)
3.18M

GILD Discussion

View Posts
jondoeuk jondoeuk 3 weeks ago
IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
👍️0
jondoeuk jondoeuk 3 weeks ago
Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
👍️0
jondoeuk jondoeuk 1 month ago
Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
👍️0
jondoeuk jondoeuk 1 month ago
I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
👍️0
jondoeuk jondoeuk 1 month ago
Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
👍️0
Monksdream Monksdream 3 months ago
GILD new 52 week high
👍️0
jondoeuk jondoeuk 4 months ago
Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
👍️0
jondoeuk jondoeuk 5 months ago
Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

There have been a number of these over the years, but nothing seems to come of them
👍️0
jondoeuk jondoeuk 5 months ago
The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
👍️0
Greedy G Greedy G 7 months ago
~bought 9/22 $80 calls .08c
👍️0
jondoeuk jondoeuk 12 months ago
Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595
👍️0
DewDiligence DewDiligence 1 year ago
Why is an oral prodrug of Remdesivir anything to get excited about?
👍️0
jondoeuk jondoeuk 1 year ago
Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html
👍️0
jondoeuk jondoeuk 1 year ago
Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.
👍️0
fink fink 1 year ago
Christmas sell off over, last day to lock in any paper tax loss. LOL

Who’s losing money here?

I think we start the trend back up into Q1
👍️0
fink fink 1 year ago
It wants $90.
I got a sell order in @88, but think it will continue up.
Gilead is moving away from HIV and more into this cancer thingy.

That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
👍️0
PennyPusher786 PennyPusher786 1 year ago
It's at a 3 year high
👍️0
fung_derf fung_derf 1 year ago
Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

I_luv_cydy

Re: fung_derf post# 3875

Tuesday, May 19, 2020 2:32:23 PM

Post#
3878
of 4839
Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.
👍️0
fink fink 1 year ago
Nice to see GILD over $80

Wonder if I should trim some? It’s been eating chit pie for some time.
Still don’t see why the spike.
👍️0
jondoeuk jondoeuk 1 year ago
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2
👍️0
Zeppo Zeppo 2 years ago
Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
👍️0
DewDiligence DewDiligence 2 years ago
GILD details why the purportedly-positive Trodelvy data from Mar 2022 weren’t:

https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a “trend in improvement” means non-statsig. OS could conceivably turn statsig in a later data cut, but that’s pretty unlikely.

The viewpoint in #msg-158260565 (from 2020) has not changed.
👍️0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
59.77 ? -1.79 (-2.91%)
Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
Bid Ask Day's Range
59.53 60.0 59.27 - 62.06
GILD Detailed Quote
👍️0
jondoeuk jondoeuk 2 years ago
ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.




👍️0
jondoeuk jondoeuk 2 years ago
Link to the audio recording https://investors.gilead.com/events/event-details/gilead-sciences-oncology-deep-dive
👍️0
jondoeuk jondoeuk 2 years ago
Oncology Deep Dive https://investors.gilead.com/static-files/332d0c81-fa18-44fa-82d3-babf96ca12d0

https://endpts.com/with-more-than-30-oncology-partners-gilead-lays-out-its-2030-vision-of-20-new-approvals/
👍️0
jondoeuk jondoeuk 2 years ago
ZUMA-12 https://www.nature.com/articles/s41591-022-01731-4

The CR rate was higher than standard frontline chemo, with just a single treatment vs. six cycles over about four months.

No reason to think long-term curve won't flatten like ZUMA-1 (which was post ~two years).

PDUFA date (for 2nd line) is April 1.
👍️0
mick mick 2 years ago
GILD News: Gilead price target slashed at Barclays following new Trodelvy data 03/10/2022 05:38:07 AM
GILD News: Current Report Filing (8-k) 03/07/2022 03:31:07 AM
GILD News: Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer 03/07/2022 03:30:00 AM
GILD News: Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD) 03/03/2022 12:10:51 AM
GILD News: Jefferies Thinks Gilead Sciences’ Stock is Going to Recover 03/02/2022 03:35:55 AM
👍️0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
58.39 ? 0.47 (0.81%)
Volume: 13,007,627 @03/11/22 7:41:31 PM EST
Bid Ask Day's Range
58.2 58.4 57.955 - 59.185
GILD Detailed Quote
👍️0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
61.33 ? 0.22 (0.36%)
Volume: 9,751,206 @02/15/22 4:17:32 PM EST
Bid Ask Day's Range
61.15 61.33 60.97 - 61.515
GILD Detailed Quote
👍️0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
63.9 ? -1.49 (-2.28%)
Volume: 12,392,843 @02/04/22 7:58:42 PM EST
Bid Ask Day's Range
63.8 64.0 63.8722 - 65.61
GILD Detailed Quote
👍️0
DewDiligence DewDiligence 2 years ago
GILD owes ViiV* $1.25B+_3% royalty on_US Biktarvy sales, as a result of a patent settlement:

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences/

The 3% royalty is a pretty big deal since Biktarvy’s had annualized US sales of $8.4B(!) in 4Q21.

* ViiV is a JV comprised of: GSK (76.5%); PFE (13.5%); and Shionogi (10%).
👍️0
DewDiligence DewDiligence 2 years ago
GILD 4Q21 results…

PR:
https://investors.gilead.com/static-files/107ab0e3-735c-4760-882f-c3647ea97ce2

CC slides:
https://investors.gilead.com/static-files/afa262c5-7eed-4944-81f5-3c2d09489d1b
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/GILD
👍️0
DewDiligence DewDiligence 2 years ago
GILD vs BMY in LBCL CAR-T—who has the edge?

https://www.fiercepharma.com/pharma/bristol-myers-squibb-breyanzi-gilead-yescarta-lock-horns-car-t-therapy-earlier-lymphoma

Both Yescarta and Breyanzi are poised to take share from stemcell transplants.
👍️0
mick mick 2 years ago
https://www.otcmarkets.com/stock/GILD
👍️0
dhbuzz dhbuzz 2 years ago
GILD and MTNB have been working on ORAL remdesivir ,results to date look outstanding ,if this is green lighted by FDA,should really give GILD a SP jump as well as MTNB

GLTA
👍️0
DewDiligence DewDiligence 2 years ago
VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

I’m not sure why it took almost a year for this trial to begin enrolling patients—the PR announcing the collaboration was issued on 1/12/21.

Please see #msg-160854272 for background.
👍️0
Michel Michel 2 years ago
I Agree: https://www.griproom.com/fun/pfizers-covid-pill-might-not-be-as-great-as-theyre-saying


Brilacidina y Remdesivir
👍️0
Ultimate01 Ultimate01 2 years ago
Showtime this week! Brilacidin is a BEAST. Remdesivir needs Brilicidin to remain relevant and in the market but Brilacidin does not need Remdesivir. Gilead has the opportunity to remain relevant and go down in history as the company that helped end the pandemic, or the company that missed the greatest opportunity.
👍️0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
66.68 ? 0.21 (0.32%)
Volume: 6,519,261 @11/05/21 7:59:38 PM EDT
Bid Ask Day's Range
66.16 66.68 65.76 - 66.87
GILD Detailed Quote
👍️0
mick mick 2 years ago
i think so they got ah good pipeline though
👍️0
Michel Michel 2 years ago
http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent


http://www.ipharminc.com/press-release/2021/10/25/innovation-pharmaceuticals-covid-19-clinical-trial-topline-results-anticipated-to-be-reported-the-week-of-november-8th

Be careful with this, the clock runs fast, pay attention to the week of November 8 or even earlier
👍️0
slimhere slimhere 2 years ago
Mick, I think we are the only ones watching GILD on iHub, whatever.

I bought more, could have bought better, but what the hay, I feel the sell off was uncalled for on dividend alone, we beat on earning as well as revenues, I believe investors wanted to know why Trodelvy results weren't part of the call, O'Day gave his reasons, he had to be political correct, plus what he said may very well be true; however, the FDA was never efficient but with Covid, they were working remote, hell, they hardly worked when they were at the office, plus, a lot of resources went to studying Covid itself as well as vaccination drugs. That's my nickel take on what's going on, here's what O'Day said.

Gilead CEO Dan O'Day says the delay isn't concerning, and is common in studies that require a certain number of patients to have their cancer worsen before data are analyzed. "Nothing has changed concerning our confidence" in the study's outcome, O'Day says. The delay could be a good sign, assuming Trodelvy patients are taking longer than expected to have their disease worsen. But RBC warns it could also be the control chemotherapy group causing the delay. Trodelvy had 3Q sales of $101M, in line with analyst projections. Trodelvy's sales are projected to be $689M in 2022, and to reach $2.1B in annual sales in 2025.
👍️0
mick mick 2 years ago
$15 under wow
👍️0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
65.92 ? -0.85 (-1.27%)
Volume: 5,723,324 @10/28/21 4:55:20 PM EDT
Bid Ask Day's Range
65.8 65.95 66.67 - 67.66
GILD Detailed Quote
👍️0
slimhere slimhere 2 years ago
5PM, we'll see how close you are, I'm hoping you're a tab low.
👍️0
mick mick 3 years ago
$gild should be over $80 to $100 imho

Gilead Sciences Inc (GILD)
68.25 ? 0.11 (0.16%)
Volume: 4,259,030 @10/08/21 6:48:20 PM EDT
Bid Ask Day's Range
67.8 68.25 67.82 - 68.41
GILD Detailed Quote
👍️0
mick mick 3 years ago
$gild should be over $80 to $100 imho

Gilead Sciences Inc (GILD)
68.25 ? 0.11 (0.16%)
Volume: 4,259,030 @10/08/21 6:48:20 PM EDT
Bid Ask Day's Range
67.8 68.25 67.82 - 68.41
GILD Detailed Quote
👍️0
dhbuzz dhbuzz 3 years ago
https://www.msn.com/en-us/health/medical/protein-found-on-infected-cells-protects-virus-from-immune-system-remdesivir-helps-prevent-hospitalization/ar-AAOSTU8?ocid=msedgdhp&pc=U531
👍️0

Your Recent History

NASDAQ
GILD
Gilead Sciences
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved